Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by duskwon Jul 23, 2012 2:45pm
178 Views
Post# 20143301

RE: RE: RE: RE: Q2 CC

RE: RE: RE: RE: Q2 CC

Call my cynical, but your post could have easily been made in 2008, 2009, 2010, 2011 or now. The problem here is it's always next's year revenue ... 

It was the same story last year - "don't worry, next years revenue will be amazing". Now we've just warned for Q2, and decreased guidance. At what point do they stop living in the future and instead size the business for the present.

And, I'm not suggesting complete elimination of R&D - but a suitable reduction is required here. It's simple business. At this point SK is simply playing with investor's capital with no regard for realistic and not so nice realities. the revenues are not there - you have to stop spending.

Bullboard Posts